CERo Therapeutics Holdings, Inc. - Form 8-K Filing Summary

On December 19, 2025, CERo Therapeutics Holdings, Inc. held a Special Meeting of Stockholders where an amendment to the 2024 Equity Incentive Plan was approved. This amendment increases the number of shares available for issuance under the plan and for incentive stock options by an additional 32,000,000 shares. The stockholders also voted on a reverse stock split, with the ratio to be determined by the Board of Directors within a range of one-for-forty to one-for-one-hundred-fifty. Additionally, a proposal to approve the issuance of common stock upon conversion of Series E convertible preferred stock in accordance with Nasdaq Listing Rule 5635 was considered. The company reported that a quorum was present with approximately 52.82% of the outstanding shares represented.